News

pharmaphorum36m
AZ claims EU okay for Imfinzi in bladder cancer
The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...
The Pharma Letter39m
AstraZeneca in talks with Summit for over $15 billion license deal
UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...
pharmaphorum43m
AZ's Imfinzi set for EU return in bladder cancer
The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...